Phenotypic and functional characterization of human memory T cell responses to Burkholderia pseudomallei

PLoS Neglected Tropical Diseases

Volumn 3, Issue 4, 2009, Pages

  Tippayawat, Patcharaporn ^a   Saenwongsa, Wipawee ^a   Mahawantung, Jirawan ^a   Suwannasaen, Duangchan ^a   Chetchotisakd, Ploenchan ^b   Limmathurotsakul, Direk ^c   Peacock, Sharon J ^c   Felgner, Philip L ^d   Atkins, Helen S ^e   Titball, Richard W ^f   Bancroft, Gregory J ^g   Lertmemongkolchai, Ganjana ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^f UNIVERSITY OF EXETER   (United Kingdom)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTIBIOTIC AGENT; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; BACTERIAL ANTIGEN;

ANTIBODY TITER; ARTICLE; BACTERIUM IDENTIFICATION; BLOOD ANALYSIS; BURKHOLDERIA PSEUDOMALLEI; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CONVALESCENCE; CYTOKINE PRODUCTION; EFFECTOR CELL; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; INFECTION RESISTANCE; LYMPHOCYTE DIFFERENTIATION; MAJOR CLINICAL STUDY; MELIOIDOSIS; MEMORY T LYMPHOCYTE; NATURAL KILLER CELL; PHENOTYPE; PROTEIN FAMILY; PROTEIN PURIFICATION; BIOSYNTHESIS; CELL CULTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; ISOLATION AND PURIFICATION; METHODOLOGY; SECRETION; T LYMPHOCYTE SUBPOPULATION; THAILAND;

ANTIGENS, BACTERIAL; BURKHOLDERIA PSEUDOMALLEI; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; KILLER CELLS, NATURAL; MELIOIDOSIS; T-LYMPHOCYTE SUBSETS; THAILAND;

EID: 65549149098     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000407     Document Type: Article

References (43)

1. White NJ (2003) Melioidosis. Lancet 361: 1715-1722.
2. Charoenwong P, Lumbiganon P, Puapermpoonsiri S (1992) The prevalence of the indirect hemagglutination test for melioidosis in children in an endemic area. Southeast Asian J Trop Med Public Health 23: 698-701.
3. Peacock SJ (2006) Melioidosis. Curr Opin Infect Dis 19: 421-428.
4. Limmathurotsakul D, Chaowagul W, Chierakul W, Stepniewska K, Maharjan B, et al. (2006) Risk factors for recurrent melioidosis in northeast Thailand. Clin Infect Dis 43: 979-986.
5. Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM (2002) Public health assessment of potential biological terrorism agents. Emerg Infect Dis 8: 225-230.
6. Jones AL, Beveridge TJ, Woods DE (1996) Intracellular survival of Burkholderia pseudomallei. Infect Immun 64: 782-790.
7. Stevens MP, Wood MW, Taylor LA, Monaghan P, Hawes P, et al. (2002) An Inv/Mxi-Spa-like type III protein secretion system in Burkholderia pseudomallei modulates intracellular behaviour of the pathogen. Mol Microbiol 46: 649-659.
8. Santanirand P, Harley VS, Dance DA, Drasar BS, Bancroft GJ (1999) Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei. Infect Immun 67: 3593-3600.
9. Lertmemongkolchai G, Cai G, Hunter CA, Bancroft GJ (2001) Bystander activation of CD8+ T cells contributes to the rapid production of IFN-gamma in response to bacterial pathogens. J Immunol 166: 1097-1105.
10. Haque A, Easton A, Smith D, O'Garra A, Van Rooijen N, et al. (2006) Role of T cells in innate and adaptive immunity against murine Burkholderia pseudomallei infection. J Infect Dis 193: 370-379.
11. Haque A, Chu K, Easton A, Stevens MP, Galyov EE, et al. (2006) A live experimental vaccine against Burkholderia pseudomallei elicits CD4+ T cell-mediated immunity, priming T cells specific for 2 type III secretion system proteins. J Infect Dis 194: 1241-1248.
12. Elvin SJ, Healey GD, Westwood A, Knight SC, Eyles JE, et al. (2006) Protection against heterologous Burkholderia pseudomallei strains by dendritic cell immunization. Infect Immun 74: 1706-1711.
13. Lauw FN, Simpson AJ, Prins JM, Smith MD, Kurimoto M, et al. (1999) Elevated plasma concentrations of interferon (IFN)-gamma and the IFN-gamma-inducing cytokines interleukin (IL)-18, IL-12, and IL-15 in severe melioidosis. J Infect Dis 180: 1878-1885.
14. Ketheesan N, Barnes JL, Ulett GC, VanGessel HJ, Norton RE, et al. (2002) Demonstration of a cell-mediated immune response in melioidosis. J Infect Dis 186: 286-289.
15. Barnes JL, Warner J, Melrose W, Durrheim D, Speare R, et al. (2004) Adaptive immunity in melioidosis: a possible role for T cells in determining outcome of infection with Burkholderia pseudomallei. Clin Immunol 113: 22-28.
16. Harland DN, Dassa E, Titball RW, Brown KA, Atkins HS (2007) ATP-binding cassette systems in Burkholderia pseudomallei and Burkholderia mallei. BMC Genomics 8: 83.
17. Harland DN, Chu K, Haque A, Nelson M, Walker NJ, et al. (2007) Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis. Infect Immun 75: 4173-4180.
18. Cheng AC, O'Brien M, Freeman K, Lum G, Currie BJ (2006) Indirect hemagglutination assay in patients with melioidosis in northern Australia. Am J Trop Med Hyg 74: 330-334.
19. Holden MT, Titball RW, Peacock SJ, Cerdeno-Tarraga AM, Atkins T, et al. (2004) Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci U S A 101: 14240-14245.
20. Eyles JE, Unal B, Hartley MG, Newstead SL, Flick-Smith H, et al. (2007) Immunodominant Francisella tularensis antigens identified using proteome microarray. Proteomics 7: 2172-2183.
21. Suputtamongkol Y, Chaowagul W, Chetchotisakd P, Lertpatanasuwun N, Intaranongpai S, et al. (1999) Risk factors for melioidosis and bacteremic melioidosis. Clin Infect Dis 29: 408-413.
22. Berard M, Tough DF (2002) Qualitative differences between naive and memory T cells. Immunology 106: 127-138.
23. Pilatz S, Breitbach K, Hein N, Fehlhaber B, Schulze J, et al. (2006) Identification of Burkholderia pseudomallei genes required for the intracellular life cycle and in vivo virulence. Infect Immun 74: 3576-3586.
24. Miyagi K, Kawakami K, Saito A (1997) Role of reactive nitrogen and oxygen intermediates in gamma interferon-stimulated murine macrophage bactericidal activity against Burkholderia pseudomallei. Infect Immun 65: 4108-4113.
25. Yang J, Murphy TL, Ouyang W, Murphy KM (1999) Induction of interferon-gamma production in Th1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur J Immunol 29: 548-555.
26. Jing L, Davies DH, Chong TM, Chun S, McClurkan CL, et al. (2008) An extremely diverse CD4 response to vaccinia virus in humans is revealed by proteome-wide T-cell profiling. J Virol 82: 7120-7134.
27. Benhnia MR, McCausland MM, Su HP, Singh K, Hoffmann J, et al. (2008) Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol 82: 3751-3768.
28. Wiersinga WJ, Dessing MC, van der Poll T (2008) Gene-expression profiles in murine melioidosis. Microbes Infect 10: 868-877.
29. Lauw FN, Simpson AJ, Prins JM, van Deventer SJ, Chaowagul W, et al. (2000) The CXC chemokines gamma interferon (IFN-gamma)-inducible protein 10 and monokine induced by IFN-gamma are released during severe melioidosis. Infect Immun 68: 3888-3893.
30. Geginat J, Lanzavecchia A, Sallusto F (2003) Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 101: 4260-4266.
31. Weekes MP, Wills MR, Sissons JG, Carmichael AJ (2004) Long-term stable expanded human CD4+ T cell clones specific for human cytomegalovirus are distributed in both CD45RAhigh and CD45ROhigh populations. J Immunol 173: 5843-5851.
32. Caccamo N, Meraviglia S, La Mendola C, Guggino G, Dieli F, et al. (2006) Phenotypical and functional analysis of memory and effector human CD8 T cells specific for mycobacterial antigens. J Immunol 177: 1780-1785.
33. Oswald-Richter K, Grill SM, Leelawong M, Tseng M, Kalams SA, et al. (2007) Identification of a CCR5-expressing T cell subset that is resistant to R5-tropic HIV infection. PLoS Pathog 3: e58. doi:10.1371/ journal.ppat.0030058.
34. Dannenberg AM Jr, Scott EM (1958) Melioidosis: pathogenesis and immunity in mice and hamsters. II. Studies with avirulent strains of Malleomyces pseudomallei. Am J Pathol 34: 1099-1121.
35. Atkins T, Prior RG, Mack K, Russell P, Nelson M, et al. (2002) A mutant of Burkholderia pseudomallei, auxotrophic in the branched chain amino acid biosynthetic pathway, is attenuated and protective in a murine model of melioidosis. Infect Immun 70: 5290-5294.
36. Brett PJ, Woods DE (1996) Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates. Infect Immun 64: 2824-2828.
37. Nelson M, Prior JL, Lever MS, Jones HE, Atkins TP, et al. (2004) Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J Med Microbiol 53: 1177-1182.
38. Chen YS, Hsiao YS, Lin HH, Liu Y, Chen YL (2006) CpG-modified plasmid DNA encoding flagellin improves immunogenicity and provides protection against Burkholderia pseudomallei infection in BALB/c mice. Infect Immun 74: 1699-1705.
39. Suparak S, Kespichayawattana W, Haque A, Easton A, Damnin S, et al. (2005) Multinucleated giant cell formation and apoptosis in infected host cells is mediated by Burkholderia pseudomallei type III secretion protein BipB. J Bacteriol 187: 6556-6560.
40. Druar C, Yu F, Barnes JL, Okinaka RT, Chantratita N, et al. (2008) Evaluating Burkholderia pseudomallei Bip proteins as vaccines and Bip antibodies as detection agents. FEMS Immunol Med Microbiol 52: 78-87.
41. Brown JS, Ogunniyi AD, Woodrow MC, Holden DW, Paton JC (2001) Immunization with components of two iron uptake ABC transporters protects mice against systemic Streptococcus pneumoniae infection. Infect Immun 69: 6702-6706.
42. Garmory HS, Titball RW (2004) ATP-binding cassette transporters are targets for the development of antibacterial vaccines and therapies. Infect Immun 72: 6757-6763.
43. Tanabe M, Atkins HS, Harland DN, Elvin SJ, Stagg AJ, et al. (2006) The ABC transporter protein OppA provides protection against experimental Yersinia pestis infection. Infect Immun 74: 3687-3691.